Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory Updates, In Brief

Executive Summary

FDA approves Acorda's MS drug: FDA approved Ampyra (dalfampridine) with the novel indication of improvement in walking ability in adults with multiple sclerosis, despite a questionably meaningful responder rate and increased risk of seizure. The Jan. 22 approval is a huge win for Acorda, which took a risk developing a MS drug with an indication that had never before been studied and for which there is no target for treatment. The approval also showcases FDA's confidence that the drug will provide a clinical benefit to some patients - a point of contention during Ampyra's advisory committee review. Despite showing that Ampyra patients had statistically significant faster walking speeds than those on placebo, FDA briefing documents noted that the magnitude of improvement was small and clinical significance was uncertain (1"The Pink Sheet," Oct. 26, 2009). Adding to the uncertainty was the drug's increased risk of seizures - a widely acknowledged safety signal for 4-aminopyridine and other pyridine compounds

You may also be interested in...



FDA's Poor On-Time User Fee Performance Weighs On Renewal Debate

FDA's poor on-time performance in reviewing new drug applications will be an issue as the agency and industry negotiate the outputs expected from the next Prescription Drug User Fee Act reauthorization

FDA's Poor On-Time User Fee Performance Weighs On Renewal Debate

FDA's poor on-time performance in reviewing new drug applications will be an issue as the agency and industry negotiate the outputs expected from the next Prescription Drug User Fee Act reauthorization

REMS Reform Looks To Be Theme Of PDUFA V: Stakeholders Call For Standardization, Earlier Notice

The biggest changes that came out of the FDA Amendments Act, the last round of Prescription Drug User Fee Act reauthorization, were FDA's augmented drug safety authorities, most specifically the Risk Evaluation and Mitigation Strategy tool. Going into the next round of PDUFA negotiations, a major focus will be on improving the implementation of the REMS program

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel